Partnering opportunities
IND enabling / early clinical development partnerships / investments
Toleris is looking for biotech or pharmaceutical companies interested in co-developing or venture capital partners interested in investing in our more advanced therapeutic programs. These are MS and MOGAD, for which we have received regulatory scientific advice, and type 1 diabetes, for which we have prioritized human candidates.
Preclinical development partnerships / early investments
Toleris is looking for early investors, biotech and academic partners to adapt the AIM Biologicals to novel indications. We offer extensive experience in human candidate or surrogate AIM Bio design, production and prioritization, and have successfully collaborated with academic and clinical partners in Europe and the US. Opportunities include myasthenia gravis, pemphigus vulgaris, stiff person syndrome, rheumatoid arthritis and many other autoimmune diseases with defined autoantigens.
Please contact us to receive further information or set up a video call!